In the largest study to date, researchers from The Institute of Cancer Research in London identified eight new gene mutations increasing the risk of developing…
Myeloma
Global biotech firm Amgen has announced that the European Commission (EC) approved a variation to the marketing authorization for Kyprolis (carfilzomib) to be used in combination with…
Advances in the molecular understanding of multiple myeloma (MM) onset and disease development have enabled the production of effective drugs, such as bortezomib,thalidomide, and lenalidomide,…
Results from a clinical trial support the use of a specific combination drug induction therapy over another three-drug treatment in multiple myeloma patients who are eligible…
Takeda Pharmaceutical Company Limited has recently received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
The Advanced Practitioners Society for Hematology and Oncology (APSHO) is presenting a series of live continuing medical education (CME) meetings, titled the “APSHO Regional Lecture…
Amgen reported findings from a post-hoc analysis of the pivotal Phase 3 ASPIRE clinical trial, highlighting the continued benefits of carfilzomib (Kyprolis), a second-generation proteasome inhibitor, plus a standard…
Researchers from Janssen Research & Development presented promising interim results from the Phase 3 MMY3004 (CASTOR) clinical trial, assessing the immunotherapy drug daratumumab (Darzalex) against standard of care…
Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple…
The Multiple Myeloma Research Foundation (MMRF) has announced that its founder, Kathy Giusti, has been appointed faculty co-chair of the Harvard Business School (HBS)…
